Bliss GVS Pharma — “Breakout Build-Up With Smart Money Flow”

(₹171) The stock is consolidating tightly near ₹170–175 after a sharp recovery from the October dip. Volume expansion + a strong OBV surge to 253M signals institutional accumulation. Price is trending above the 20-EMA, showing sustained bullish momentum. Immediate resistance: ₹185, followed by ₹205. Support lies at ₹158. A breakout above ₹185 could trigger a fast move. Fundamental View: Bliss operates in antifungals, contraceptives, and dermatology, with strong export markets in Africa & Asia. Margins have improved due to product mix and lower raw material pressure. Debt levels remain low, and FY24–FY25 revenue growth remains steady in double digits. Management commentary remains confident on scaling contract manufacturing. Analyst Sentiment: → Rating: Moderately Bullish → Target Range: ₹195–₹215 → Key Risk: High export dependency.